Back to search results

Phase 1 Study of IM-1021 for Advanced Cancer

This study is testing a new treatment called IM-1021 for people with advanced solid tumors or blood cancers (like B-cell lymphomas). IM-1021 is an antibody-drug conjugate (a type of targeted therapy that delivers a drug directly to cancer cells). The main goal is to find out how safe IM-1021 is and what dose works best. Researchers will also look for early signs of how well it fights cancer. You might be able to join if you are at least 18 years old and have advanced cancer that has been diagnosed by a doctor. This study is currently recruiting about 117 participants.

Study design
This is a Phase 1, first-in-human study that is open-label, meaning both you and the study team will know which treatment you are receiving. It will involve about 117 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety and tolerability will be measured from the first dose to 37 days after your last dose of study treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06823167

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

Recruiting
PHASE1Ages 18+InterventionalTreatment
Immunome, Inc.
~190 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:IM-1021

At a glance

Recruiting sites
24 of 24 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and tolerability of IM-1021 in participants with advanced lymphomas and advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs)
Measured over From first dose to 37 days following last dose of study treatment
+1 more outcome measured

Conditions

Solid Malignancies
Hematologic Malignancies

Explore related trials

Breast CarcinomaDiffuse Large B-Cell LymphomaFollicular LymphomaHematologic NeoplasmLiposarcomaLung Non-Small Cell CarcinomaMalignant MesotheliomaMalignant Ovarian NeoplasmMantle Cell LymphomaPancreatic CarcinomaSmall Lymphocytic LymphomaSolid Neoplasm

NCT06823167

Where you'd take part

This study runs at 24 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Brown University

    Providence, Rhode Islandno site contact published

    Recruiting

  • Centre Leon-Berard

    Lyon, Franceno site contact published

    Recruiting

  • City Of Hope

    Duarte, Californiano site contact published

    Recruiting

  • Colorado Blood Cancer Institute

    Denver, Coloradono site contact published

    Recruiting

  • Copenhagen University Hospital

    Copenhagen, Denmarkno site contact published

    Recruiting

  • Emory Winship Cancer Institute

    Atlanta, Georgiano site contact published

    Recruiting

  • Gabrail Cancer Center

    Canton, Ohiono site contact published

    Recruiting

  • Gustave Roussy

    Villejuif, Franceno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Immunome Medical Monitor
[email protected]
425.939.7410
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Mantle cell lymphoma (MCL)
Diffuse large B-cell lymphoma (DLBCL) (including Richter's transformation)
Follicular lymphoma
Small lymphocytic lymphoma (SLL)
Marginal zone lymphoma
Pancreatic cancer
Non-squamous non-small cell lung cancer (NSCLC)
Malignant mesothelioma
Epithelial ovarian cancer. Participants with fallopian tube and/or peritoneal malignancies are also eligible.
Triple-negative breast cancer.
Liposarcoma

What this trial measures

  • Safety and tolerability of IM-1021 in participants with advanced lymphomas and advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs)From first dose to 37 days following last dose of study treatment

    Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0, including serious adverse events (SAEs), AEs of interest (AEI), AEs leading to discontinuation, and deaths

  • Determine the recommended dose(s) and schedule(s) of IM-1021 for further developmentFrom first dose to 37 days following last dose of study treatment

    Type, frequency, seriousness, and severity of AEs graded using the NCI-CTCAE v6.0, including SAEs, AEIs, AEs leading to discontinuation, and deaths